Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

McKesson Corporation agreed to acquire Precision Medicine Group, adding a variety of drug development and commercialization capabilities.

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

ByZachary Zubulake

August 25th 2026

What professionals need to know about the hold of RGX-121 (clemidsogene lanparvovec)for Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome by the FDA

Must-Knows from the RGX-121 Hold

ByZachary Zubulake

August 24th 2026

n-nitrosodimethylamine molecular structure, 3d model molecule, dimethylnitrosamine, structural chemical formula view from a microscope | Image Credit: ©Сергей Шиманович -stock.adobe.com

From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk

ByChris Williams

August 24th 2026

Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia recieved accelerated approval from the FDA.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

ByZachary Zubulake

August 20th 2026

Pasatru (garetosmab-grts) has been approved by the FDA to treat symptoms of fibrodysplasia ossificans progressiva

How a 63-Patient Trial Delivered an FDA Approval

ByZachary Zubulake

August 20th 2026

Characterization of the Performance of Bin Blenders Part 1 of 3: Methodology

Articles in this issue

Related Content

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

Must-Knows from the RGX-121 Hold

From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

How a 63-Patient Trial Delivered an FDA Approval

Trending on Pharmaceutical Technology

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

Must-Knows from the RGX-121 Hold

From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing